{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:23:29Z","timestamp":1792106609667,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pituitary metastases are rare, often deriving from lung or breast cancer owing to the upper vena cava proximity. Pituitary metastases can manifest with signs and symptoms of pituitary tumors, consequent to mass effect (headache, visual impairment) and\/or hormonal alterations (hyperprolactinemia, hypopituitarism, and diabetes insipidus). Immune checkpoint inhibitors burst immunity against tumors, significantly increasing patients\u2019 survival, but their autoimmune side effects frequently involve the skin, the gastrointestinal tract, and the endocrine glands (pituitary, thyroid, pancreas).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 77-year-old Caucasian man had undergone trans-nasal sphenoidal surgery for a nonsecreting pituitary macroadenoma in 2001, without remnant or endocrine deficits. In 2016, he was operated for a shoulder melanoma. In February 2018, imaging evaluation demonstrated metastases in lung, liver, and femur. Therefore, treatment with pembrolizumab (anti-programmed death 1) was scheduled in May 2018, but, before starting this therapy, a brain computed tomography performed for a sudden loss of consciousness detected a sellar mass of 17\u00a0\u00d7\u00a012\u00a0mm, which extended to the pituitary stalk and compressed the optic chiasma. Focused magnetic resonance imaging confirmed the size and characteristics of the lesion, while emergency evaluation of the hormonal profile demonstrated an impairment of adrenal and thyroid function. The pituitary lesion demonstrated a remarkable shrinkage (8\u00a0\u00d7\u00a06\u00a0mm), which was confirmed by subsequent imaging evaluations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first case reporting on effectiveness of immune checkpoint inhibitors in a patient with pituitary metastasis from a melanoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-03150-4","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:42:46Z","timestamp":1636591366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Giuseppe","family":"Giuffrida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"issue":"4","key":"3150_CR1","first-page":"E8","volume":"16","author":"DR Fassett","year":"2004","unstructured":"Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus. 2004;16(4):E8.","journal-title":"Neurosurg Focus"},{"key":"3150_CR2","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/ERC-19-0263","volume":"27","author":"A Angelousi","year":"2020","unstructured":"Angelousi A, Alexandraki K, Kyriakopoulos G, et\u00a0al. Neoplastic metastases to the endocrine glands. Endocr Relat Canc. 2020;27:R1\u201320.","journal-title":"Endocr Relat Canc"},{"issue":"2","key":"3150_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1210\/jc.2003-030395","volume":"89","author":"J Komninos","year":"2004","unstructured":"Komninos J, Vlassopoulou V, Protopapa D, et\u00a0al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab. 2004;89(2):574\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"3150_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11102-014-0552-2","volume":"18","author":"W He","year":"2015","unstructured":"He W, Chen F, Dalm B, et\u00a0al. Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary. 2015;18:159\u201368.","journal-title":"Pituitary"},{"key":"3150_CR5","unstructured":"Shimon I. Metastatic spread to the pituitary. Neuroendocrinology. 2020 Feb 27. [Epub ahead of print]."},{"key":"3150_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/00004728-199305000-00018","volume":"17","author":"NA Mayr","year":"1993","unstructured":"Mayr NA, Yuh WTC, Muhonen MG, et\u00a0al. Pituitary metastases. J Comput Assist Tomogr. 1993;17:432\u20137.","journal-title":"J Comput Assist Tomogr"},{"key":"3150_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF00588159","volume":"34","author":"O Schubiger","year":"1992","unstructured":"Schubiger O, Haller D. Metastases to the pituitary-hypotalamic axis. An MR study of 7 symptomatic patients. Neuroradiology. 1992;34:131\u20134.","journal-title":"Neuroradiology"},{"key":"3150_CR8","first-page":"971","volume":"16","author":"Y Koshimoto","year":"1995","unstructured":"Koshimoto Y, Maeda M, Naiki H, et\u00a0al. MR of pituitary metastasis in a patient with diabetes insipidus. AJNR Am J Neuroradiol. 1995;16:971\u20134.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"3150_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3171\/jns.1998.89.1.0069","volume":"89","author":"A Morita","year":"1998","unstructured":"Morita A, Meyer FB, Laws ER. Symptomatic pituitary metastases. J Neurosurg. 1998;89(1):69\u201373.","journal-title":"J Neurosurg"},{"key":"3150_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2176\/nmc.44.112","volume":"44","author":"Y Iway","year":"2004","unstructured":"Iway Y, Yamanaka K, Honda Y, Matsusaka Y. Radiosurgery for pituitary metastases. Neurol Med Chir. 2004;44:112\u20136.","journal-title":"Neurol Med Chir"},{"key":"3150_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/(SICI)1097-0045(19970901)32:4<241::AID-PROS3>3.0.CO;2-M","volume":"32","author":"M Losa","year":"1997","unstructured":"Losa M, Grasso Giugni E, Mortini P, Acerno S, Giovanelli M. Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment. Prostate. 1997;32:241\u20135.","journal-title":"Prostate"},{"key":"3150_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10555-011-9280-5","volume":"30","author":"TJ Stewart","year":"2011","unstructured":"Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metast Rev. 2011;30:125\u201340.","journal-title":"Cancer Metast Rev"},{"key":"3150_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"key":"3150_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et\u00a0al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med"},{"key":"3150_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, et\u00a0al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190\u2013209.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3150_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenn\u00ec A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannav\u00f2 S. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest. 2019;42(7):745\u201356.","journal-title":"J Endocrinol Invest"},{"issue":"No. 5","key":"3150_CR17","first-page":"e297","volume":"5","author":"AJ Estrada","year":"2019","unstructured":"Estrada AJ, Sibley SD, Drake TC. Symptomatic pituitary metastases: two case reports with contrasting clinical presentations. AACE Clin Case Rep. 2019;5(No. 5):e297.","journal-title":"AACE Clin Case Rep"},{"key":"3150_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.wneu.2020.04.138","volume":"139","author":"PP Mattogno","year":"2020","unstructured":"Mattogno PP, Giordano M, D\u2019Alessandris QG, Ktari O, Giampietro A, Rigante M, Gessi M, et\u00a0al. Solitary metastatic melanoma of the pituitary gland: report of two cases and literature review. World Neurosurg. 2020;139:378\u201381.","journal-title":"World Neurosurg"},{"key":"3150_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2176\/nmc.cr2012-0068","volume":"53","author":"K Masui","year":"2013","unstructured":"Masui K, Yonezawa T, Shinji Y, Nakano R, Miyamae S. Pituitary apoplexy caused by hemorrhage from pituitary metastatic melanoma: case report. Neurol Med Chir (Tokyo). 2013;53:695\u20138.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"3150_CR20","doi-asserted-by":"crossref","unstructured":"Anson D, Norton J, Chaucer B, Bansal S. Ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and QTc prolongation. Case Rep Oncol Med 2019;7896749.","DOI":"10.1155\/2019\/7896749"},{"issue":"10","key":"3150_CR21","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang J, Cuaron J, Beal K, Cohen M, et\u00a0al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. 2018;103(10):3925\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"3150_CR22","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, et\u00a0al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"key":"3150_CR23","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, Du Z, et\u00a0al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016;7:76565\u201376.","journal-title":"Oncotarget"},{"key":"3150_CR24","first-page":"989","volume":"13","author":"PF Wang","year":"2018","unstructured":"Wang PF, Wang TJ, Yang YK, et\u00a0al. The expression profile of PD-L1 and CD8 lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol. 2018;13:989\u201395.","journal-title":"J Neurooncol"},{"key":"3150_CR25","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ, et\u00a0al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19:1511\u201321.","journal-title":"Neuro Oncol"},{"issue":"9","key":"3150_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623\u201335.","journal-title":"Nat Rev Immunol"},{"key":"3150_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/cancers12030586","volume":"12","author":"CG Brahm","year":"2020","unstructured":"Brahm CG, van Linde ME, Enting RH, et\u00a0al. The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review. Cancers. 2020;12:586.","journal-title":"Cancers"},{"key":"3150_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ajco.13100","volume":"15","author":"S Parakh","year":"2019","unstructured":"Parakh S, Randhawa M, Nguyen B, et\u00a0al. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. Asia Pac J Clin Oncol. 2019;15:26\u201330.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3150_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/EDBK_100005","volume":"35","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016;35:116\u201322.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3150_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2018.36.15_suppl.2020","volume":"36","author":"DA Reardon","year":"2018","unstructured":"Reardon DA, Neuberg DS, Keskin DB, et\u00a0al. Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine. J Clin Oncol. 2018;36:2020.","journal-title":"J Clin Oncol"},{"key":"3150_CR31","doi-asserted-by":"publisher","first-page":"106148","DOI":"10.1016\/j.intimp.2019.106148","volume":"80","author":"L Yang","year":"2010","unstructured":"Yang L, Liu L, Wu X, Guo X, Yang Y, Wang T. Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: a meta-analysis. Int Immunopharmacol. 2010;80:106148.","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03150-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:46:49Z","timestamp":1636591609000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03150-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3150"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03150-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report did not include any treatment differing from the management of the case suggested by current guidelines, so approval from ethics committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"555"}}